• Press Release

FDA Grants BioMarin Orphan Drug Designation for NAGLU Fusion Protein, BMN 250, for the Treatment of MPS IIIB (Sanfilippo Syndrome Type B)

• News Post

Hope for a Brighter Future: Kainen’s Story

• Page

ESG Roadmap

• Page

INTERNAL: Web Request Form for Commercial Sites Form

• Page

Report an Adverse Event

• Publication

The Impact of Pre-existing Immunity on the Non-clinical Pharmacodynamics of AAV5-Based Gene Therapy

Brian R. Long, Krystal Sandza, Jennifer Holcomb, Lucy Crockett, Gregory M. Hayes, Jeremy Arena, Carls Fonck, Laurie S. Tsurda, Becky Schweighardt, Charles A. O’neill, Stephen Zoog, Christian Vettermann

• Publication

Gene Therapy with BMN 270 Results in Therapeutic Levels of FVIII in Mice and Primates and Normalization of Bleeding in Hemophilic Mice

Stuart Bunting, Lening Zhang,1 Lin Xie, Sherry Bullens, Rajeev Mahimkar, Sylvia Fong, Krystal Sandza, Danielle Harmon, Bridget Yates, Britta Handyside, Choong-Ryoul Sihn, Nicole Galicia, Laurie Tsuruda, Charles A. O’Neill, Anil Bagri, Peter Colosi, Shinong Long, Gordon Vehar, and Barrie Carte

• Page

Hypochondroplasia

• Page

Board of Directors

• Page

Idiopathic Short Stature

• Press Release

BioMarin Announces Agreement With Repligen for Pre-clinical Compounds

• Press Release

FDA Advisory Committee Recommends Approval for BioMarin’s Vimizim(TM) for the Treatment of Patients With Morquio A Syndrome

• Press Release

BioMarin Establishes Commercial Operations in Europe

• Press Release

Forbes Ranks BioMarin 10th Most Innovative Company in the World

• Press Release

Patient Enrollment Complete for Phase I/II Clinical Trial for GALNS for Morquio A Syndrome

• Press Release

BioMarin to Present at the Cowen and Company 30th Annual Health Care Conference

• Press Release

BioMarin and Serono Form Strategic Alliance for the Development and Commercialization of Phenoptin(TM) and Phenylase(TM)

• Press Release

BioMarin Announces Third Quarter 2015 Financial Results and Company Update

• Press Release

BioMarin Announces FDA Advisory Committee to Review Drisapersen for Treatment of Patients With Duchenne Muscular Dystrophy Amenable to Exon 51 Skipping

• Press Release

FDA Advisory Committee Discusses Clinical Data Package for BioMarin’s Kyndrisa(TM) (drisapersen) for the Treatment of Duchenne Muscular Dystrophy Amenable to Exon 51 Skipping